Skip to main content
editorial
. 2006 Dec;92(12):1717–1719. doi: 10.1136/hrt.2006.089789

Table 1 Stem cell trials.

Trial Randomised Method of LVEF assessment Length of follow up (months) Group Mean basal EF (%) Mean final EF (%) Change in EF p Value
BOOST12 Yes MRI 6 Control, n = 30 51.3 52.0 0.7
Active, n = 30 50.0 56.7 6.7 0.026
MAGIC13 Yes SPECT and echo 6 Control, n = 1 33.0 39.0 6
Cells+ G‐CSF, n = 7 48.7 55.1 7 0.005
G‐CSF only, n = 3 45.4 44.0 −1.5 0.007
TOPCARE‐AMI11 No LV angiography 4 Control , n = 11 51.0 53.5 2.5
Active, n = 19 51.6 60.1 8.5 0.003
Janssens et al16 Yes MRI and echo 4 Control, n = 34 46.9 49.1 2.2
Active, n = 32 48.5 51.8 3.4 0.36
ASTAMI20 Yes MRI 6 Control, n = 50 53.6 58.1 4.5
Active, n = 50 54.8 56.2 1.4 0.51
TCT STAMI Yes Echo 6 Control, n = 10 58.2 56.3 −1.9
Active, n = 10 53.8 58.6 4.8 <0.05
Observational studies
Baks et al18 NA MRI 5 n = 22 48 55 7 <0.05
Ingkanisorn et al19 NA MRI 2 n = 33 52 57 5 <0.002

EF, ejection fraction; G‐CSF, granulocyte‐colony stimulating factor; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; NA, not applicable; SPECT, single photon emission computed tomography.